METIS TECHBIO-P Surges Over 6% in Early Trading Following $1.6 Billion Preclinical TCE Licensing Deal

Deep News07-03

Shares of METIS TECHBIO-P (ASX: 07666) climbed more than 6% during the morning session.

At the time of writing, the stock was up 5.85% to HK$14.29, with a turnover of HK$5.8649 million.

Major Licensing Agreement Announced

The company recently announced the first significant achievement of its strategic alliance with the global health investment and innovation platform Deerfield Management, aimed at accelerating the global development of next-generation immunotherapies.

METIS TECHBIO-P has entered into a global exclusive licensing agreement with Boulevard Bio, a U.S.-based biotech company under Deerfield.

Under this agreement, the company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on product net sales.

Record-Breaking Transaction

Public disclosures indicate this transaction sets a new record for the value of a single overseas licensing deal for a preclinical TCE project by a Chinese pharmaceutical company.

It is also viewed as a significant milestone in the internationalization of China's AI drug delivery innovations.

The company's proprietary NanoForge platform has achieved deep integration of AI protein design, delivery system development, and novel therapy creation.

Having gained validation from top-tier global capital and industry partners, this development signals that AI-driven drug delivery platforms are progressing from early-stage technical validation to the realization of global commercial value.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1155258968?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 11:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1155258968","market":"other","top_or_hot":-1,"title":"METIS TECHBIO-P Surges Over 6% in Early Trading Following $1.6 Billion Preclinical TCE Licensing Deal","media":"Deep News","content":"<p>Shares of <b>METIS TECHBIO-P</b> (<b>ASX: 07666</b>) climbed more than 6% during the morning session.<br><br>At the time of writing, the stock was up 5.85% to HK$14.29, with a turnover of HK$5.8649 million.<br><br>\n<b>Major Licensing Agreement Announced</b><br><br>The company recently announced the first significant achievement of its strategic alliance with the global health investment and innovation platform Deerfield Management, aimed at accelerating the global development of next-generation immunotherapies.<br><br><b>METIS TECHBIO-P</b> has entered into a global exclusive licensing agreement with Boulevard Bio, a U.S.-based biotech company under Deerfield.<br><br>Under this agreement, the company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on product net sales.<br><br>\n<b>Record-Breaking Transaction</b><br><br>Public disclosures indicate this transaction sets a new record for the value of a single overseas licensing deal for a preclinical TCE project by a Chinese pharmaceutical company.<br><br>It is also viewed as a significant milestone in the internationalization of China's AI drug delivery innovations.<br><br>The company's proprietary NanoForge platform has achieved deep integration of AI protein design, delivery system development, and novel therapy creation.<br><br>Having gained validation from top-tier global capital and industry partners, this development signals that AI-driven drug delivery platforms are progressing from early-stage technical validation to the realization of global commercial value.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>METIS TECHBIO-P Surges Over 6% in Early Trading Following $1.6 Billion Preclinical TCE Licensing Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMETIS TECHBIO-P Surges Over 6% in Early Trading Following $1.6 Billion Preclinical TCE Licensing Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-07-03 11:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>METIS TECHBIO-P</b> (<b>ASX: 07666</b>) climbed more than 6% during the morning session.<br><br>At the time of writing, the stock was up 5.85% to HK$14.29, with a turnover of HK$5.8649 million.<br><br>\n<b>Major Licensing Agreement Announced</b><br><br>The company recently announced the first significant achievement of its strategic alliance with the global health investment and innovation platform Deerfield Management, aimed at accelerating the global development of next-generation immunotherapies.<br><br><b>METIS TECHBIO-P</b> has entered into a global exclusive licensing agreement with Boulevard Bio, a U.S.-based biotech company under Deerfield.<br><br>Under this agreement, the company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on product net sales.<br><br>\n<b>Record-Breaking Transaction</b><br><br>Public disclosures indicate this transaction sets a new record for the value of a single overseas licensing deal for a preclinical TCE project by a Chinese pharmaceutical company.<br><br>It is also viewed as a significant milestone in the internationalization of China's AI drug delivery innovations.<br><br>The company's proprietary NanoForge platform has achieved deep integration of AI protein design, delivery system development, and novel therapy creation.<br><br>Having gained validation from top-tier global capital and industry partners, this development signals that AI-driven drug delivery platforms are progressing from early-stage technical validation to the realization of global commercial value.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1155258968","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1155258968","pubTimestamp":1783048969,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of METIS TECHBIO-P (ASX: 07666) climbed more than 6% during the morning session.At the time of writing, the stock was up 5.85% to HK$14.29, with a turnover of HK$5.8649 million. Major...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","07666":"剂泰科技-P"},"translate_title":"METIS TECHBIO-P在达成价值16亿美元的临床前TCE许可协议后早盘飙升超过6%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"07666":1},"content_text":"Shares of METIS TECHBIO-P (ASX: 07666) climbed more than 6% during the morning session.At the time of writing, the stock was up 5.85% to HK$14.29, with a turnover of HK$5.8649 million.\nMajor Licensing Agreement AnnouncedThe company recently announced the first significant achievement of its strategic alliance with the global health investment and innovation platform Deerfield Management, aimed at accelerating the global development of next-generation immunotherapies.METIS TECHBIO-P has entered into a global exclusive licensing agreement with Boulevard Bio, a U.S.-based biotech company under Deerfield.Under this agreement, the company will receive an upfront payment of $20 million and is eligible for up to $1.6 billion in development, regulatory, and commercial milestone payments, plus tiered royalties on product net sales.\nRecord-Breaking TransactionPublic disclosures indicate this transaction sets a new record for the value of a single overseas licensing deal for a preclinical TCE project by a Chinese pharmaceutical company.It is also viewed as a significant milestone in the internationalization of China's AI drug delivery innovations.The company's proprietary NanoForge platform has achieved deep integration of AI protein design, delivery system development, and novel therapy creation.Having gained validation from top-tier global capital and industry partners, this development signals that AI-driven drug delivery platforms are progressing from early-stage technical validation to the realization of global commercial value.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1155258968","isCrawlerRequest":true}